AGMB — AgomAb Therapeutics NV
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2020932 ·
Belgium
Last close
$10.51
Market Cap
$517.60M
52W High
$17.82
52W Low
$8.75
ADV30
153,063
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 290,923,000 | 221,588,000 | 25,547,000 |
| Dec 2025 | 0 | — | -16,527,000 | -17,401,000 | 153,706,000 | 86,418,000 | 22,804,000 |
| Sep 2025 | — | — | — | — | 165,631,000 | 129,585,000 | 18,700,000 |
| Dec 2024 | 0 | — | -11,814,000 | -11,732,000 | 206,358,000 | 171,459,000 | 18,277,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,609,000
Investing CF
$-30,367,000
Financing CF
$81,829,000
CapEx
$-363,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-181,714,000
Inventory
—
Receivables
$4,085,000
ST Investments
$30,096,000
EBIT TTM
$-29,423,000
Pretax Income TTM
$-29,129,000
Interest Exp TTM
$-294,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -59,275,000 | -62,547,000 | 153,706,000 | 22,804,000 | 130,902,000 | -51,741,000 |
| Dec 2024 | 0 | -48,021,000 | -46,267,000 | 206,358,000 | 18,277,000 | 188,081,000 | -46,828,000 |
| Dec 2023 | 0 | -31,190,000 | -11,390,000 | 171,259,000 | 19,824,000 | 151,435,000 | -24,592,000 |
| Dec 2022 | 0 | -22,634,000 | -8,142,000 | 100,995,000 | 34,747,000 | 66,248,000 | -18,967,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.07
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRME | Prime Medicine, Inc. | $525.99M | $2.90 | — |
| AUTL | Autolus Therapeutics plc | $493.73M | $1.86 | — |
| RGNX | REGENXBIO Inc. | $488.50M | $7.40 | — |
| ENTX | Entera Bio Ltd. | $475.27M | $2.74 | — |
| ALLO | Allogene Therapeutics, Inc. | $570.06M | $1.65 | — |
News headlines (Yahoo Finance, 1h cache)
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
2026-09-14 20:05 · Yahoo
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
2026-09-11 20:05 · Yahoo
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
2026-08-10 20:07 · Yahoo
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
2026-08-06 20:01 · Yahoo
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
2026-07-02 20:06 · Yahoo
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease
2026-06-23 20:05 · Yahoo
Agomab to Participate in Upcoming Conferences
2026-05-14 11:30 · Yahoo
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
2026-04-23 22:14 · Yahoo
AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447
2026-04-12 18:46 · Yahoo
Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease
2026-06-23 21:32 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.